206 related articles for article (PubMed ID: 33960437)
1. NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility.
Saliba M; Katabi N; Dogan S; Xu B; Ghossein RA
Histopathology; 2021 Oct; 79(4):650-660. PubMed ID: 33960437
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors.
Oishi N; Kondo T; Vuong HG; Nakazawa T; Mochizuki K; Kasai K; Inoue T; Tahara I; Hirokawa M; Miyauchi A; Katoh R
Hum Pathol; 2016 Jul; 53():51-7. PubMed ID: 26980032
[TBL] [Abstract][Full Text] [Related]
3. The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma.
Nakaguro M; Tanigawa M; Hirai H; Yamamoto Y; Urano M; Takahashi RH; Sukeda A; Okumura Y; Honda S; Tasaki K; Shimizu A; Tsukahara K; Tada Y; Matsubayashi J; Faquin WC; Sadow PM; Nagao T
Am J Surg Pathol; 2021 Jul; 45(7):885-894. PubMed ID: 33481388
[TBL] [Abstract][Full Text] [Related]
4. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
[TBL] [Abstract][Full Text] [Related]
5. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
6. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
Pareja F; Toss MS; Geyer FC; da Silva EM; Vahdatinia M; Sebastiao APM; Selenica P; Szatrowski A; Edelweiss M; Wen HY; Mihai R; Varga Z; Foschini MP; Rubin BP; Ellis IO; Chandarlapaty S; Jungbluth AA; Brogi E; Weigelt B; Reis-Filho JS; Rakha EA
Histopathology; 2020 May; 76(6):865-874. PubMed ID: 31887226
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
9. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
[TBL] [Abstract][Full Text] [Related]
10. Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry.
Crescenzi A; Fulciniti F; Bongiovanni M; Giovanella L; Trimboli P
Endocr Pathol; 2017 Mar; 28(1):71-74. PubMed ID: 28064410
[TBL] [Abstract][Full Text] [Related]
11. Ectopic Thyroid Tissue: Immunohistochemistry and Molecular Analysis.
Lin DM; Javidiparsijani S; Vardouniotis A; Buckingham L; Reddy SB; Gattuso P
Appl Immunohistochem Mol Morphol; 2018; 26(10):734-739. PubMed ID: 28362711
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry.
Kim M; Jeon S; Jung CK
Endocr Pathol; 2023 Jun; 34(2):247-256. PubMed ID: 37040004
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
[TBL] [Abstract][Full Text] [Related]
14. Multi-dimensional immunoproteomics coupled with in vitro recapitulation of oncogenic NRAS
Belousov PV; Afanasyeva MA; Gubernatorova EO; Bogolyubova AV; Uvarova AN; Putlyaeva LV; Ramanauskaite EM; Kopylov AT; Demin DE; Tatosyan KA; Ustiugova AS; Prokofjeva MM; Lanshchakov KV; Vanushko VE; Zaretsky AR; Severskaia NV; Dvinskikh NY; Abrosimov AY; Kuprash DV; Schwartz AM
Cancer Lett; 2019 Dec; 467():96-106. PubMed ID: 31326556
[TBL] [Abstract][Full Text] [Related]
15. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
17. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
[No Abstract] [Full Text] [Related]
18. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
[TBL] [Abstract][Full Text] [Related]
19. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
20. High specificity and sensitivity of NRAS Q61R immunohistochemistry (IHC) in melanomas.
Just PA; Pouliquen C; Audebourg A; Laurent-Roussel S; Carlotti A; Dupin N; Vacher-Lavenu MC; Vidaud M; Terris B; Pasmant E
J Am Acad Dermatol; 2016 Mar; 74(3):572-3. PubMed ID: 26892658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
